Fred Alger Management’s Protagonist Therapeutics PTGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-7,650
Closed -$938K – 466
2026
Q2
$938K Buy
+7,650
New +$799K ﹤0.01% 367
2025
Q2
– Sell
-7,477
Closed -$362K – 470
2025
Q1
$362K Buy
+7,477
New +$313K ﹤0.01% 375
2023
Q3
– Sell
-21,719
Closed -$600K – 518
2023
Q2
$600K Buy
21,719
+10,114
+87% +$253K ﹤0.01% 391
2023
Q1
$267K Buy
+11,605
New +$195K ﹤0.01% 418

Other funds holding PTGX

Fred Alger Management's PTGX Position: Q3 2026 in Review

Fred Alger Management sold out of Protagonist Therapeutics (PTGX) in Q3 2026, closing a stake of 7,650 shares — an estimated $938K sold.

Fred Alger Management first reported a position in PTGX in Q1 2023 and held it in 4 quarters. The position peaked at $938K in Q2 2026. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • Fred Alger Management reported no remaining Protagonist Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Fred Alger Management sold 7,650 Protagonist Therapeutics shares in Q3 2026, an estimated $938K.
  • Fred Alger Management first reported a position in Protagonist Therapeutics in Q1 2023 and held it in 4 quarters.
  • Fred Alger Management's Protagonist Therapeutics position peaked at $938K in Q2 2026.
  • 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on Fred Alger Management's 13F filing for Q3 2026, filed 16 Nov 2026.